CLEARWATER, Fla., July 18 /PRNewswire/ -- minSURG Corporation, producers of the TruFUSE(R) percutaneous facet stabilization procedure, announced today the creation of minSURG International, Incorporated. The international division has been established in response to global demand for the TruFUSE procedure and products.
CEO, Jim Doulgeris said, "Distributors from Canada, Brazil, Germany, Greece, South Korea, Netherlands, Singapore, Taiwan, Turkey and Japan have expressed strong interest in providing the benefits of our minimally invasive and percutaneous spinal fusion to their populations suffering from debilitating back pain. Sales to Turkey and Greece have already been initiated."
Peter Sontag, the current Chairman of minSURG's parent company, was appointed as President of the new international division. Sontag's extensive international business experience, having lived abroad for over 22 years, along with his understanding of diverse cultures makes him the ideal candidate for this position. According to Sontag, TruFUSE must respond to the demands of the international marketplace after successfully engaging North America. "The dynamics of numerous medical reimbursement systems around the world are as unique as the languages spoken in their various countries. We will implement dynamic solutions to international distribution parallel to the success we have demonstrated here," Sontag said.
The TruFUSE procedure uses specially designed human bone dowels to stop facet joints from moving, which is intended to eliminate or dramatically reduce back pain caused by a variety of reasons. TruFUSE is also used to supplement other back surgeries when more invasive or destructive means are not required. The TruFUSE procedure is intended to fuse the facet joints through a natural healing process for a long-term solution. Because TruFUSE causes minimal tissue damage, it does not preclude other options, including non-surgical alternatives, and TruFUSE can be used earlier than other, more invasive spine fusion methods. Over 2,000 patients have been treated to date.
For more information on TruFUSE, please visit the Web site at http://www.trufuse.com or call (813) 318-0565 ext. 216.
|SOURCE minSURG Corporation|
Copyright©2008 PR Newswire.
All rights reserved